BioEcho next generation products for the Life Sciences —
Convenience by design

DNA Extraction 2.0 - Invest in the Future

BioEcho Life Science GmbH serves the Genomic Research and Molecular Diagnostics markets. We develop, manufacture and distribute kits and reagents for manual and automated DNA and RNA isolation and processing.

Extraction of genomic material (nucleic acids: DNA, RNA) is a base technology applied in many ways in modern Life Sciences and Biotech, such as diagnosis of inherited and acquired diseases (cancer, infection), therapy accompanying (companion) diagnostics, genome research, forensics, and food testing. The market and the number of applications as well as the sample throughput are growing extremely fast. The mode of extraction and purification, i. e. the purity of the prepared DNA, determines the quality of downstream operations (PCR, NGS, other enzymatic manipulations) and its results as well as the speed and throughput of the entire processes. In order to meet the growing demand on high-quality nucleic acid preparation in genomic research and Molecular Diagnostics, faster and simpler processes are required for the molecular biology of the future.

Facing these challenges, BioEcho has developed a new base technology that fulfills all these demands of a state-of-the-art medical and research practice: a single-step purification that enables dramatically faster sample processing and delivers genomic DNA preparations in a purity that has never been reached before. And it's ecologically responsible, too! Our technology works without aggressive chemicals and reduces plastic waste by more than 70%.

Our first products based on this single-step technology are available - and many more are to come in the near future.

We strongly believe that our strengths will convince you:

To prepare for future accelerated company growth, BioEcho is currently preparing its second financing round. A selection of some of BioEcho’s technical assets has been listed above. Here are a few more reasons why an investment into BioEcho may be attractive to you:

Investor Relations

BioEcho is currently funded by

  • The team of founders
  • Private investors
  • A Crowdinvesting campaign on medifundo

Our private investors include

DresInvest GmbH
FS Life Science Investment UG
We welcome private as well as Venture Capital and corporate Venture Capital investors! To explore further investment opportunities, please contact us at!

BioEcho Life Sciences GmbH has qualified for the INVEST 2.0 programme launched by the German Federal Ministry of Economics.

Business Angel investors receive a 20% tax-free refund of investments into BioEcho!
Click here for further information:

Dr. Frank Schäfer and Dr. Markus Müller

A look into the future:
The BioEcho management, Dr. Frank Schäfer and Dr. Markus Müller

high yield and speed of process

Our data speak for themselves:
high yield and speed of process

BioEcho in "Handelsblatt"
"Die Erbgut-Reiniger" (The Genome Cleaner) was the title of the full-page coverage of BioEcho in the well-known business magazine "Handelsblatt"
See the article as PDF File

Contact Distributors Terms and Conditions/AGB Privacy Policy/Datenschutz Imprint/Impressum Newsletter